Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy

Dr Michail Ignatiadis - Institut Jules Bordet, Brussels, Belgium
Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy ( Dr Michail Ignatiadis - Institut Jules Bordet, Brussels, Belgium )
15 Jan 2024

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer

Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya
CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer ( Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya )
10 Jan 2024

Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients

Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients ( Dr Oleg Gluz -  Krankenhaus Bethesda, Mönchengladbach, Germany )
28 Dec 2023

Significant clinical benefits observed with revumenib monotherapy in relapsed/refractory KMT2Ar acute leukaemia

Dr Ibrahim Aldoss - City of Hope National Medical Center, Duarte, USA
Significant clinical benefits observed with revumenib monotherapy in relapsed/refractory KMT2Ar acute leukaemia ( Dr Ibrahim Aldoss - City of Hope National Medical Center, Duarte, USA )
24 Dec 2023

Ide-cell enhances health-related quality of life for refractory multiple myeloma

Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium
Ide-cell enhances health-related quality of life for refractory multiple myeloma ( Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium )
24 Dec 2023

Zanidatamab, palbociclib and fulvestrant show positive results in treating HER2+/HR+ mBC

Dr Santiago Escrivá-de-Romani - Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Zanidatamab, palbociclib and fulvestrant show positive results in treating HER2+/HR+ mBC ( Dr Santiago Escrivá-de-Romani - Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain )
20 Dec 2023

Toripalimab and metronomic chemotherapy show efficacy in treating in HER2-negative metastatic breast cancer

Dr Hongnan Mo - National Cancer Center/Cancer Hospital, Beijing, China
Toripalimab and metronomic chemotherapy show efficacy in treating in HER2-negative metastatic breast cancer ( Dr Hongnan Mo - National Cancer Center/Cancer Hospital, Beijing, China )
20 Dec 2023

BrECADD combined with PET2-guided treatment sets a new benchmark for the treatment of newly diagnosed advanced-stage cHL

Dr Peter Borchmann - University Hospital Cologne, Cologne, Germany
BrECADD combined with PET2-guided treatment sets a new benchmark for the treatment of newly diagnosed advanced-stage cHL ( Dr Peter Borchmann - University Hospital Cologne, Cologne, Germany )
19 Dec 2023

Ponatinib is superior to imatinib in combination with chemotherapy for newly diagnosed Ph+ ALL

Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA
Ponatinib is superior to imatinib in combination with chemotherapy for newly diagnosed Ph+ ALL ( Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA )
19 Dec 2023

Cancer care in Needle Hospital, Hargeisa, Somaliland

Gebrekirstos Hagos - Needle Hospital, Hargeisa, Somaliland
Cancer care in Needle Hospital, Hargeisa, Somaliland ( Gebrekirstos Hagos - Needle Hospital, Hargeisa, Somaliland )
5 Dec 2023

Relapsed refractory multiple myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India
Relapsed refractory multiple myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )
5 Dec 2023

First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/M cervical cancer

Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain
First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/M cervical cancer ( Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain )
4 Dec 2023